01 / 01


REGEnLIFE focuses their therapeutic strategy on the brain-gut axis for the Alzheimer’s disease

Feb , 15
REGEnLIFE focuses their therapeutic strategy on the brain-gut axis for the Alzheimer’s disease

REGEnLIFE won a trophy at the Inn’Ovations contest in the “Product of the Future of the Year” category. This regional prize was awarded to the company at the closing of the Occitanie Innov event in Labège on January 31, 2019.


REGEnLIFE’s mission is to develop innovative and responsible technologies responding to public health issues. Its goal is to bring to the market a treatment capable of modifying the progression of neurodegenerative pathologies such as Alzheimer’s disease. Currently, an interdisciplinary team of ten people is working with different partners covering a wide range of fields such as medicine, physical sciences and engineering.

A major epidemic

Alzheimer’s disease has a rapid epidemiological progression. Patients do not benefit from any curative treatment. In addition, few treatments have entered the clinical trial process and too often lead to therapeutic failure.

A “beyond-the-brain” therapeutic strategy

REGEnLIFE builds on the hypothesis that the brain-gut axis is involved in the development of Alzheimer’s disease or brain aging; and that certain forms of electromagnetic emissions could prevent or even treat this disease in a non-invasive way. The innovation was tested through preclinical experiments yielding convincing and promising results.

International visibility

In October 2019, REGEnLIFE participated to the international conference ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) in Barcelona, Spain. Clinical teams from all over the world came together to share their latest findings with the aim of identifying the therapeutic strategies of tomorrow. REGEnLIFE seized the opportunity to present its latest scientific work conducted with the companies Amylgen (Montpellier) and Vaiomer (Toulouse). These results focused on the therapeutic impact of this medical technology on the gut microbiota. In light of these results and the suggested importance of the role of the gut microbiota in many neurological disorders, it should now be considered as a new therapeutic target for the treatment of Alzheimer’s disease. In addition, the combination of multiple targets currently appears as a promising therapeutic strategy for disorders as complex as neurodegenerative disorders. REGEnLIFE also presented new scientific work at the BiOS / SPIE Photonics West conference in San Francisco in February 2019.

 A pilot study at the University Hospital of Montpellier

Today, a group of patients is benefiting from the medical device developed by REGEnLIFE at the CHU of Montpellier as part of a first clinical trial with Audrey Gabelle, MD, PhD as the principal investigator. New patients are currently being recruited.

New perspectives

From the beginning of this adventure, REGEnLIFE, led by Guillaume Blivet, has been incubated at BIC Montpellier, accompanied by the agency AD’OCC and supported by the BPI and the Occitanie region. Financing is underway to enable the company to pursue its R&D work in an ambitious manner. Given that Alzheimer-type dementia accounts for more than 45 million cases worldwide, the success of REGEnLIFE could lead to significant spin-offs in terms of activities.

Post a comment

Your email address will not be published. Required fields are marked *